Table I.

Distribution and prognosis of patients for each score of SSG survival scoring system.

A, Distribution of prognostic factors
Prognostic factors		Kagoshima	SSG	P-valuea
Skeletal metastasis				<0.01
Single		65	146
Multiple		80	505
Organ metastasis				<0.01
Absent		107	384
Present		38	267
Primary tumor				<0.01
Breast, kidney, thyroid, myeloma, lymphoma		51	360
Other		94	291
Karnofsky score				<0.01
≥70		26	338
<70		119	313
Impending fracture		122	156	<0.01
Pathological fracture		23	495
SSG survival score
Group A, 3–4		42	N/A
Group B, 1–2		90	N/A
Group C, 0		13	N/A
B, SSG survival scoring
Prognostic factors	Points	Sum	Groups	Estimated survival (months)
Skeletal metastasis				>12
Single	1
Multiple	0	4	A
Organ metastasis				3–6
Absent	1	3
Present	0	2	B
Breast, kidney, thyroid, myeloma, lymphoma				<3
Yes	1	1
No	0	0	C
Karnofsky score
≥70	1
<70	0
C, SSG scoring
Prognostic score	Months	Survival rate (%)		95% CI
Group A, 3–4	3	80.2		0.69–0.93
	6	65.5		0.50–0.81
	12	59.0		0.43–0.75
	24	27.4		0.10–0.44
Group B, 1–2	3	66.7		0.56–0.77
	6	55.5		0.44–0.67
	12	32.6		0.21–0.44
	24	26.0		0.15–0.37
Group C, 0	3	43.3		0.15–0.71
	6	8.7		0.00–0.25

^aMeasured with Fisher's exact probability test. SSG, Scandinavian Sarcoma Group; CI, confidence interval.